2nd International Congress on Psychopharmacology

Dr. Jayne Bailey, is a researcher in Psychopharmacology Unit, University of Bristol. Current primary area of interest is the development of a human experimental model for use in the discovery of novel agents for the treatment of anxiety. This has led to the development and validation of the inhalation of 7.5% CO2 as a model of anxiety which produces psychological and physiological effects. These effects can be attenuated by clinical treatments. In addition, she is part of the teaching faculty for the “Good Practice in Clinical Research“ course, which is a joint training course between the United Bristol Healthcare Trust and the University of Bristol. Until recently, Jayne was for many years the Editorial Manager of the international journal, the Journal of Psychopharmacology and is a Member of the British Association for Psychopharmacology and the European College of Neuropsychopharmacology.

Professor and Director of the Neurochemical Research Unit Professor of Neuroscience CIHR, Canada Research Chair in Neurochemistry and Drug Development Research Interests Mechanisms of action of antidepressant and anxiolytic drugs. Biochemical bases of psychiatric disorders, with emphasis on depression and anxiety disorders. Development of analytical techniques for measuring amino acids, biogenic amines, neuroactive steroids psychiatric drugs and their metabolites in tissues and body fluids Drug metabolism and drug-drug interactions: He is interested in the role of metabolism in the actions of psychiatric drugs since many of them are extensively metabolised and/or undergo metabolic interactions with other drugs that are coadministered. In addition, metabolites often contribute significantly to the therapeutic effects and/or side effect profiles of the drugs. Roles of amino acids (primarily GABA, glutamate, serine glycine and alanine) in the etiology and pharmacotherapy of neuropsychiatric disorders. The development and testing of potential new neuroprotective agents

Professor Tim Crow is a British psychiatrist and researcher. Much of his research is related to the causes of schizophrenia. He is the Honorary Director of the Prince of Wales International Centre for Research into Schizophrenia and Depression. He qualified at the Royal London Hospital in 1964 and obtained a PhD in the University of Aberdeen, Scotland, in 1970. He is a fellow of the Royal Colleges of Physicians and Psychiatrists and the Academy of Medical Sciences. Professor Crow was for twenty years Head of the Division of Psychiatry of the MRC Clinical Research Centre at Northwick Park and then a member of the External Scientific staff of the Medical Research Council in Oxford. Tim Crow?s long term research interests are in the nature and causation of the major psychoses. These illnesses are characterised by the presence of delusions and hallucinations and disorders of thinking and generally have an onset in early and middle adult life. Encompassing schizophrenia and manic-depressive psychosis these disorders are common, affecting around 2% of the population in the course of a lifetime. In the first CT scan study in 1976 Professor Crow and colleagues at Northwick Park demonstrated that there are structural changes (eg a degree of enlargement of the cerebral ventricles) in individuals who have suffered from schizophrenia. Much subsequent work with MRI scans and in post-mortem brain studies has confirmed this and suggests that the changes are in the cerebral cortex and particularly are related to the subtle asymmetries that are characteristic of the human cortex. What is the origin of these changes? In earlier work Professor Crow considered but was able to rule out a viral causation. There is a genetic component but the nature has been obscure. Professor Crow?s particular recent contribution has been the proposal that the origins of the psychoses relate particularly to those characteristics eg cerebral asymmetry that are associated with the specifically human capacity for language.

Bill Deakin graduated in medicine at Leeds University in 1973. He took an extra year in his training to obtain a 1st in Physiology and this focussed his interest in biology on the brain and the organisation of behaviour. From there, he specialised in Psychiatry and joined the Clinical Research Centre at Northwick Park, London to further his training and enter the field of brain research. Bill Deakin has been Professor of Psychiatry for 10 years. His PhD research at the National Institute for Medical Research, London investigated how distinct 5HT (serotonin) neurone pathways in the rat brain have different functions in regulating adaptive, coping responses to stress. Deakin moved to the University of Manchester as Senior Lecturer in the early 1980s to continue 5HT research but in clinical studies of volunteers and patients with depression, anxiety and antisocial behaviour. Bill Deakin developed an interest in the neurobiology of schizophrenia and how the neurotransmitter of the grey matter, glutamate, might be involved in generating the bizarre symptoms such as hearing voices and being deluded. Prof. Bill Deakin heads Neuroscience Research in the Division of Psychiatry. An important focus of his group is to use modern imaging techniques to directly visualise 5HT and glutamate working in the brain. The group can also visualise how these neurotransmitters modify how the brain processes information. They are now investigating these effects in patients with anxiety, depression and antisocial behaviour.

Currently Senior Lecturer in Psychiatry and Director of Programme for the Translational Neuroscience of Psychosis, Neuroscience and Psychiatry Unit, University of Manchester & Honorary Consultant Psychiatrist and Lead Consultant, Psychiatric Intensive Care Unit, Bolton Salford Trafford Mental Health Services NHS Trust (BST-MHS NHS Trust). Clinical duty includes; providing full psychiatric services to a catchment area of over 60,000. Providing specialist tertiary Psychopharmacology Consultation services for patients with treatment resistant Schizophrenia and Mood Disorders. Research duty include; (i) Investigations into the neurobiological mechanisms and psychopharmacology of refractory mental states using neuroimaging techniques and clinical trials (ii) The clinical psychopharmacology of glutamate and nitric oxide in experimental-psychosis and schizophrenia (iii) Investigating behavioural and neuroanatomical correlates of immediate early genes activation in experimental psychosis induced by ketamine and phencyclidine. He has over 100 peer-reviewed publications and main administrative duties include; (i) Serving as Clinical Problems and Case Reports Section Editor of the Journal of Psychopharmacology and Editor for the Supplements. (ii) Associate editor Bulletin of Clinical Psychopharmacology (iii) Serving as secretary to the Special Interest Group in Psychopharmacology (SIGP) of the Royal College of Psychiatrists. (iv) Member of the Clinical Governance Steering Group of the BST-MHS NHS Trust

Dr. Goodwin trained in medicine and completed a DPhil in physiology at Oxford. After training in psychiatry he spent 10 years as Clinical Scientist and Consultant Psychiatrist in the Medical Research Council (MRC) Brain Metabolism Unit in Edinburg, Scotland. He has served as a member on the Wellcome Trust Neurosciences Panel, the Council of the British Association for Psychopharmacology and the Clinical Fellowships Panel and Advisory Board of the MRC. He is currently president of the British Association for Psychopharmacology. Dr. Goodwin has published more than 200 refereed papers and book chapters. Dr. Goodwin has been W.A. Handley Professor of Psychiatry at the University of Oxford, Oxford, UK since 1996. His research interests are in the neurobiology and treatment of mood disorder. He has helped develop the basis for a large-scale pragmatic clinical trial in bipolar affective disorder, BALANCE.

Dr. Kutcher is an internationally renowned expert in the area of adolescent mental health and a national and international leader in mental health research, advocacy, training, policy, and health services innovation. Currently he is the Sun Life Financial Chair in Adolescent Mental Health and Director of the WHO Collaborating Center in Mental Health Training and Policy Development at Dalhousie University. A medical graduate of Mc Master University Dr. Kutcher did his postgraduate training in psychiatry at the University of Toronto and a McLaughlin fellowship at the Brain Metabolism Unit of Edinburgh University. Dr. Kutcher most recently served as Associate Dean of International Medical Development & Research with Dalhousie University ?s Faculty of Medicine. At Dalhousie, he has been Chair of the Department of Psychiatry and has had a leading role in the creation of the Life Sciences Development Association, the Brain Repair Centre, and the International Health Office. Dr. Kutcher also served as Clinical-Academic Director of the Capital District Health Authority?s Mental Health Program. In 2003, he was chosen by Atlantic Progress Magazine as one of the top 20 innovators in Atlantic Canada. Amongst his many awards and honours, he was named as the 2004 National Champion of Mental Health, Research by the Canadian Alliance on Mental Illness and Mental Health and received the 2005 Dr. Mary Seeman award from the Canadian Psychiatry Research Foundation in recognition of his lifetime achievements in mental health work. Dr. Kutcher was a founding member of the Canadian Association for Mood and Anxiety Treatment , the Advisory Board for the Institute of Neuroscience , Mental Health and Addictions (Canadian Institutes of Health Research), the Science Advisory Committee of NeuroScience Canada , and the Canadian Coalition for Global Health Research. In addition to his participation in numerous national and international organizations he currently serves as a board member of the Canadian Society for International Health, the Canadian Psychiatric Research Foundation and Interhealth Canada.

Dr. Norbert Muller was born in Berlin, after Abitur study of psychology and medicine in Munich (Ph.D.,M.D.). Since 1982 training in psychiatry, psychotherapy and neurology at the University Hospital of LMU Munich. Since 1990 senior psychiatrist and consultant, Psychiatric Hospital, LMU Munich. 1993 habilitation in the field of psychoneuroimmunology. Head of the schizophrenia special ward since 1998; Responsible for the new-building and reconstruction of the Kraepelinian Hospital. 2000 Professor of psychiatry. Current affiliation: vice-chair of the Hospital of Psychiatry and Psychotherapy, LMU Munich. Since 2003 President of the German Society of Biological Psychiatry. Current research activities: Psychoneuroimmunology, Movement disorders, Pathogenesis and therapy of schizophrenia, Psychopharmacology More than 250 publications in the field Research Awards: “Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie“ 1997 “Kraepelin Research Award“ 2001

David Nutt is currently Professor of Psychopharmacology and Head of the Department of Community Based Medicine at the University of Bristol. He received his undergraduate training in medicine at Cambridge and Guy's Hospital, and continued training in neurology to MRCP. After completing his psychiatric training in Oxford, he continued there as a lecturer and then later as a Wellcome Senior Fellow in psychiatry. He then spent two years as Chief of the Section of Clinical Science in the National Institute of Alcohol Abuse and Alcoholism in NIH, Bethesda, USA. On returning to England in 1988 he set up the Psychopharmacology Unit in Bristol, an interdisciplinary research grouping spanning the departments of Psychiatry and Pharmacology. Their main research interests are in the brain mechanisms underlying anxiety, depression and addiction and the mode of action of therapeutic drugs. He is currently a member of the Advisory Council on the Misuse of Drugs (ACMD), and Chair of its Technical Committee, on the Council and President-Elect of the European College of Neuropsychopharmacology (ECNP) and a Director of the ?European Certificate in Anxiety and Mood Disorders? and the ?Masters in Affective Disorders? Courses jointly administered by the Universities of Maastrict, Bristol and Florence. In addition, he is the Editor of the Journal of Psychopharmacology, advisor to the British National Formulary and a Past-President of the British Association of Psychopharmacology (BAP). He was also a member of the Independent Inquiry into the Misuse of Drugs Act 1971, chaired by Viscountess Runciman that reported in 2000 and a member of the Committee on Safety of Medicines (CSM) from 2000 ? 2005. From January 2006 he has taken on the role as Director of Bristol Neuroscience.

Trevor Robbins was appointed in 1997 as the Professor of Cognitive Neuroscience at the University of Cambridge. He was elected to the Chair of Expt. Psychology (and Head of Department) at Cambridge from October 2002. He is also Director of the newly-established Cambridge MRC Centre in Behavioural and Clinical Neuroscience, the main objective of which is to inter-relate basic and clinical research in Psychiatry and Neurology for such conditions as Parkinson?s, Huntington?s, and Alzheimer?s diseases, frontal lobe injury, schizophrenia, depression, drug addiction and developmental syndromes such as attention deficit/hyperactivity disorder. He is a Fellow of the British Psychological Society and the Academy of Medical Sciences. He has been President of the European Behavioural Pharmacology Society (1992-1994) and he won that Society?s inaugural Distinguished Scientist Award in 2001. He was also President of the British Association of Psychopharmacology from 1996 to 1997. He has edited the journal Psychopharmacology since 1980 and joined the editorial board of Science in Jan. 2003. He has been a member of the Medical Research Council (UK) and chaired the Neuroscience and Mental Health Board from 1995 until 1999. He has been included on a list of the 100 most cited neuroscientists by ISI. He has published nearly five hundred full papers in scientific journals and has co-edited three books (Psychology for Medicine: The Prefrontal Cortex; Executive and Cognitive Function, and Disorders of Brain and Mind). Trevor W. Robbins' research interests span the areas of cognitive neuroscience, behavioural neuroscience and psychopharmacology. His main work focuses on the functions of the frontal lobes of the brain and their connections with other regions, including the so-called brain reward systems which have been discovered in both animals and humans. He is also interested in establishing how drugs work to produce changes in brain chemistry, and how these affect behaviour. Two particular current interests are characterising beneficial effects of drugs on cognition, as may occur with ?cognitive enhancing? drugs used clinically and deleterious effects of drugs of abuse, such as cocaine and amphetamine, which may lead to possible long-term intellectual impairment.

Dr. Atilla Turgay finished his education in medicine, general psychiatry and child & adolescent psychiatry at Hacettepe University. He has continued his work at various educational institutes in the United States of America, such as New York Medical College, Wayne State University (Detroit), Michigan State University and Ottawa, McMaster and Toronto Universities in Canada, for the last 28 years. Dr. Atilla Turgay is professor at the Faculty of Medicine of Toronto University as well as Director of Psychiatric Research at The Scarborough Hospitals. He is also currently Director of the Attention Deficiency and Hyperactivity Clinic, Director of the Training and Research Institute, Director of Research at the Department of Psychiatry and Head of Science of Child and Adolescent Psychiatry at the same Hospital. He is a founding member and current Education Director of the Canadian Attention Deficiency Education and Research Organisation. He has written books along with Dr. Sunar Birs?z, ?Medicinal Treatment in Psychiatry?, Dr. Eyup Ercan, ?Unhappy Child: Depression in Child and Youth Stages of Development? and Dr. Bengi Semerci, ?Attention Deficiency and Hyperactivity Disorder from Infancy to Adulthood?. He is also a contributing author to the book entitled Canadian ADHD Treatment Guidelines. Dr. Turgay has been found to be the top researcher in 10 international medicine researches and has undertaken multi-centre studies with Ritalin, Ritalin SR, Metadate, Biphentin, Concerta, Strattera and Risperidone. Risperidone has had a leading role in the treatment of DEHB, Behavioural Disorder and Autism in Children and Youths and has been found in many publications. He has over 200 peer-reviewed publications. He has also received many research and outstanding service awards from many International organisations.

Professor Cowen is Professor of Psychopharmacology at the University of Oxford Medical School and Honorary Consultant in Psychiatry at the Warneford Hospital, Oxford, where he also holds the post of MRC Clinical Scientist in the Department of Psychiatry. Professor Cowen graduated as a doctor in 1974, and became a Fellow of the Royal College of Psychiatrists in 1991. He is also a Fellow of the Academy of Medical Sciences. Before his current position, he was a Registrar in Psychological Medicine at King's College Hospital, London, and Research Fellow in Clinical Psychopharmacology at the Radcliffe Infirmary, Oxford. His research interests relate to the psychopharmacology of mood and eating disorders. Professor Cowen's main interests are in the biochemistry and treatment of mood disorders, particularly the pharmacological management of resistant depression. His group has special expertise in the use of pharmacological challenge tests to assess the effects of both mood disorder and antidepressant treatments on brain serotonin function. More recently, in collaboration with Professor Paul Grasby at the MRC Cyclotron Unit, the group has been able to use ligand PET imaging to assess the role of brain 5-HT1A receptors in vulnerability to mood disorder and the mechanism of antidepressant action.